Auris Medical Holding AG (NASDAQ:EARS) shares dropped 3.2% during mid-day trading on Thursday . The stock traded as low as $3.95 and last traded at $3.96, with a volume of 96,772 shares. The stock had previously closed at $4.09.

EARS has been the topic of several recent research reports. Leerink Swann restated a “buy” rating and issued a $12.00 price target on shares of Auris Medical Holding AG in a research report on Wednesday, June 15th. Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The company’s market capitalization is $140.41 million. The stock’s 50 day moving average price is $3.76 and its 200 day moving average price is $4.10.

Auris Medical Holding AG (NASDAQ:EARS) last announced its earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. During the same period in the prior year, the business posted ($0.28) EPS. On average, equities research analysts expect that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.